Globally, the market for anticoagulant was priced at US$ 30,773.2 million in the year 2021 and is estimated to the extent of US$ 57,337.5 million by the end of the year 2028 at a CAGR of 9.4% from 2022 to 2028. The market of anticoagulant is witnessing robust development owing to the developing incidence of prolonged disease in need for anticoagulants worldwide. Furthermore, increase in emphasis on the growth of new anticoagulants and increasing elderly (geriatric) population worldwide is anticipated to fuel the market growth. Though, factors like aide effects related with anticoagulants and strict government rules are anticipated to hinder the market growth of anticoagulants across the world.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5486
Global Anticoagulant Market: Regional Insights
On the basis of geography, the market of anticoagulant worldwide is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
Amongst region, North America is anticipated to have the major market share in the predicted period owing to the rise in prevalence of prolonged diseases, mainly cardiovascular diseases (CVD’s) and increase in use of new oral anticoagulants (NOACs) in the region. For example, as per AHA (American Heart Association) report of October 2021, more than 2,300 people in U.S die owing to CVDs every day, which is 1 death in 38 seconds on an average. Therefore, with the rise in incidence of CVDs, need for coagulants are also rising, thus pushing the market growth.
Asia Pacific is also anticipated to experience substantial growth of anticoagulant’s market worldwide owing to the rise in incidence of CVD’s and rise in need for anticoagulants in this region. For example, anticoagulants plays vital role in treating CVDs. India’s problem of cardiovascular disease is highest across the world. As per National Center for Biotechnology Information, the number of deaths in a year from cardiovascular disease in India is anticipated to rise from 2.26 Mn in the year 1990 to 4.77 Mn in the year 2020. This has raised the need for anticoagulants in the region.
Global Anticoagulant Market Drivers
Increasing incidence of prolonged diseases worldwide is anticipated to fuel the market growth of the anticoagulant across the world in the predicted period. For example, DOACs (Direct oral anticoagulants) are needed in preventing and treating CVDs. Direct oral anticoagulants are anticoagulation pharmacotherapy needed for preventing thrombosis in many cardiovascular reference. As per WHO (World Health Organization), CVDs are the main root of death worldwide, taking a projected 17.9 Mn lives every year. This is anticipated to raise the need for anticoagulants worldwide.
Rise in need for anticoagulants worldwide is anticipated to fuel the market growth of the anti-coagulant worldwide in the predicted period. For example, Natco Pharma in December 2020 announced the introduction of an antiblood clot tablet known as Rivaroxaban, which is used in treating and preventing clotting of blood. The tablet is at present sold by Bayer with the brand name of Xarelto in the msrket of India. Natco has introduced RPIGAT in strengths of four, 20 mg, 15 mg, 10 mg, and 2.5 mg. The new oral anti-coagulant, Rivaroxaban is following the Natco’s mission of making medicines affordable that can be easily accessed by everyone, as released from a Natco Pharma.
Global Anticoagulant Market Opportunities
Increasing in emphasis on the growth of new anticoagulants is anticipated to offer substantial opportunities of growth for the companies in the market of anticoagulant across the world. For example, with the increase in the problem of prolonged diseases across the world, the need for safe and real anticoagulants is also rising with increased pace. The United States National Institutes of Health (NIH) in March 2020, started the remaining last three Phase III medical trials of blood thinners (anticoagulant) in preventing life-threatening clotting of blood in adults with the coronavirus disease (COVID-19)
Increasing elderly population worldwide is anticipated to provide profitable opportunities of growth for the companies in the market of anticoagulant across the globe. For example, the need for unplanned and non-invasive treatments is increasing among the elderly population which has augmented the need for coagulants across the world. AS per WHO, by the end of the year 2030, 1 in every 6 people in the globe will age 60 years and more and by the end of the year 2050, the population of the world of people aging 60 years and more will get double which is 2.1 Bn.
Buy This Premium Report with Amazing Offer (Up to 25% Off) @ https://www.coherentmarketinsights.com/insight/buy-now/5486
Global Anticoagulant Market Trends
There is a rise in need for DOACs (direct oral anticoagulants) worldwide. The expansion and the introduction of DOACs (direct oral anticoagulants) signify a vast development in the anticoagulation field. Furthermore, the use of NOACs (new oral anticoagulant) is rising or has been raised in the emerging countries and is expected to exhibit same fashion in the predicted period due to the high liking of new oral anticoagulants over the warfarin.
Furthermore, the application of anticoagulants is rising, due to the rising application of plasma in the pharmaceutical industry. Without this, in clinical usages also, anticoagulants are needed. These extensive usages from anti-tumor and anti-inflammatory in order to prevent the infectious disease and the application of nano-carriers for delivery of drug. This fashion is anticipated to last in the predicted period, pushing the growth of the market.
Global Anticoagulant Market Restraints
The after effects related with some anticoagulant are anticipated to hinder the market growth of the anticoagulant worldwide. For example, medicines of anticoagulant can result in after effects which may cause serious complications. Common after effects in relation to anticoagulants is bleeding. On the basis of medicine used, other possible risks also occur. They cause upset stomach, nausea, diarrhea and others.
Strict regulations of the government are anticipated to hamper market growth of the anticoagulant. The application of oral anticoagulants is being observed for negative drug activities. For example, US FDA (United States Food and Drug Administration) uses normal surveillance meanings in relation to anticoagulant bleeding trials in post marketing and analysis by epidemiology, to avail the exactness of diagnostic and coding by procedure to arrest anticoagulant-associated bleeding activities.
Global Anticoagulant Market Segmentation
Globally, the market report of anticoagulant is divided into drug class, geography and application.
On the basis of drug class, the market is classified into Heparin, Low-molecular- weight Heparin (LMWH), Novel Oral Anticoagulants (NOACs), and Vitamin K Antagonist. Amongst which, the market of Novel Oral Anticoagulants (NOACs) Segment is anticipated to control the market of anticoagulant in the predicted period and this is credited to the rise in use of NOACs which helps in preventing clot formation and protecting a person from many types of strokes.
The segment of Heparin and Low-Molecular-Weight Heparin (LMWH) Segment is also anticipated to experience substantial growth in the coming future and this due to the rise in problem of prolonged diseases. LMWH aids in treating cancer-associated clot of blood, since it is more in effect than warfarin.
On the basis of application, the market is classified into Pulmonary Embolism, Deep Vein Thrombosis (DVT), Atrial Fibrillation/Myocardial Infarction (Heart Attack), and Other Applications. Amongst which, the segment of Atrial Fibrillation/Myocardial Infarction (Heart Attack) Segment is anticipated to control the market in the predicted period and this is credited to the rise in prevalence of CVDs worldwide.
The segment of Deep Vein Thrombosis (DVT) Segment is anticipated to experience substantial growth in the coming future and this is due to the rise in application of anticoagulants. Anticoagulant therapy rests the backbone of clinical therapy for DVT (deep venous thrombosis)
Global Anticoagulant Market: Key Developments
Janssen Pharmaceuticals Companies of Johnson & Johnson announced in October 2019 that the US FDA permitted Xarelto (Rivaroxaban) in preventing venous thromboembolism (VTE).
Bristol-Myers Squibb-Pfizer Alliance declared in March 2019 results of Phase 4 AUGUSTUS trial assessing Eliquis (apixaban) versus vitamin K antagonists (VKAs) in person with non-valvular atrial fibrillation (NVAF) and the new ACS (acute coronary syndrome) or undergoing PCI (percutaneous coronary intervention)
Global Anticoagulant Market: Key Companies Insights
Globally, the market of anticoagulant is very much competitive in type. This is accredited to the increase in need or rise in use of anticoagulants worldwide, consequently, companies are emphasizing on introducing new products in the market.
The main companies in the market of anticoagulants worldwide includes Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.
Get your Customized Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/5486
Table of Contents:
- Research Objectives and Assumptions
- Research Objectives
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of chronic diseases across the globe
- Stringent government regulations
- Rise in focus on the development of novel anticoagulants
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
Check Out More Related Reports:
Acute ischemic stroke therapeutics market
Anticoagulant reversal drugs market
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Phone: U.S.: +1-206-701-6702